Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020)

被引：4

作者：

Sader, Helio S. ^{[1
]}

Castanheira, Mariana ^{[1
]}

Duncan, Leonard R. ^{[1
]}

Mendes, Rodrigo E. ^{[1
]}

机构：

[1] JMI Labs, North Liberty, IA 52317 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2023年 / 105卷 / 01期

关键词：

MRSA; skin and skin structure infection; pneumonia; ceftaroline; Staphylococcus aureus; VANCOMYCIN;

D O I：

10.1016/j.diagmicrobio.2022.115820

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Ceftaroline and comparators were tested against 9,268 Staphylococcus aureus isolates from 33 United States hospitals (2018-2020). Ceftaroline (MIC50/90, 0.25/1 mg/L) susceptibility ranged from 95.4% (pneumonia) to 98.5% (skin and skin structure) and was 97.2% overall. Ceftaroline retained potent and broad-spectrum activ-ity against methicillin-resistant isolates, with a 93.4% overall susceptibility. (c) 2022 Published by Elsevier Inc.

引用

页数：4

共 50 条

[21] In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States
Farrell, David J.
Mendes, Rodrigo E.
Bensaci, Mekki
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 93 (01) : 85 - 88
[22] Comparative In Vitro Activities of Ceftaroline and Tedizolid against Clinical Strains of Staphylococcus aureus and Enterococcus: Results from the China Antimicrobial Surveillance Network (CHINET) in 2018
Guo, Yan
Yang, Yang
Zheng, Yonggui
Wu, Shi
Yin, Dandan
Zhu, Demei
Hu, Fupin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
[23] Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in US Medical Centers: Results from Five Years of the AWARE Surveillance Program
Sader, Helio S.
Flamm, Robert K.
Streit, Jennifer M.
Farrell, David J.
Jones, Ronald N.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 2458 - 2461
[24] In vitro activity of ceftaroline against methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates from a tertiary hospital in Greece
Tychala, Areti
Protonotariou, Efthymia
Meletis, Georgios
Tsoha, Anna
Mantzana, Paraskevi
Vasilaki, Olga
Kagkalou, Georgia
Skoura, Lemonia
NEW MICROBIOLOGICA, 2021, 44 (02): : 125 - 128
[25] EVALUATION OF THE IN VITRO ACTIVITY OF CEFTAROLINE AND COMPARATORS AGAINST STREPTOCOCCUS PNEUMONIAE ISOLATES FROM THE UNITED STATES: RESULTS FROM 10 YEARS OF THE AWARE SURVEILLANCE PROGRAM (2011-2020)
Sader, Helio
Carvalhaes, Cecilia
Streit, Streit
Shortridge, Dee
Mendes, Rodrigo
Castanheira, Mariana
CHEST, 2021, 160 (04) : 513A - 513A
[26] Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019
Sader, Helio S.
Streit, Jennifer M.
Mendes, Rodrigo E.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2021, 99 (01)
[27] Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020)
Sader, Helio S.
Castanheira, Mariana
Carvalhaes, Cecilia G.
Arends, S. J. Ryan
Mendes, Rodrigo E.
MICROBIAL DRUG RESISTANCE, 2022, 28 (09) : 935 - 940
[28] Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015-2018)
Sader, H. S.
Jones, R. N.
CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (05) : 658 - 659
[29] Activity of dalbavancin tested against Staphylococcus spp. and β-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Biedenbach, Douglas J.
Ross, James E.
Fritsche, Thomas R.
Sader, Helio S.
Jones, Ronald N.
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (03) : 998 - 1004
[30] Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers
Sader, H. S.
Watters, A. A.
Fritsche, T. R.
Jones, R. N.
JOURNAL OF CHEMOTHERAPY, 2008, 20 (01) : 28 - 32

← 1 2 3 4 5 →